India · Delayed Price · Currency is INR Dhanuka Agritech Earnings Call Transcripts
Fiscal Year 2026
-
Q4 FY 2025-26 saw 9% revenue growth and record EBITDA margin, aided by a GST refund and disciplined cost management. Guidance for FY 2026-27 is low double-digit growth, with new product launches and improved biostimulant sales expected to drive performance.
-
Q3 FY 2026 saw a year-over-year decline in revenue and profit due to weak agrochemical demand, regulatory challenges, and adverse weather. Despite this, new product launches, Dahej plant ramp-up, and strong cash reserves position the company for recovery and long-term growth.
-
Q2 FY 2026 saw revenue and profit decline YoY due to erratic rainfall and regulatory hurdles in biostimulants, with herbicide sales most affected. Guidance for FY 2026 is flattish revenue, stable gross margins, and a 100 bps EBITDA margin decline, while new product launches and digital initiatives continue.
-
Revenue grew 7% year-over-year in Q1 FY26, with EBITDA and PAT also rising. Despite subdued herbicide demand and high channel inventory, management maintains double-digit growth guidance for FY26, with a slight EBITDA margin decline expected. Dividend and buyback completed.
Fiscal Year 2025
-
Revenue grew 15.7% year-over-year to INR 2,035 crore, with EBITDA up 27% and PAT up 24%. Global expansion accelerated via Bayer molecule acquisition, and higher double-digit growth is guided for FY 2026, though gross margin is expected to decline by 100 bps.
-
Q3 FY25 saw double-digit revenue and profit growth, driven by new product launches and strong specialty molecule performance, despite challenging agro-climatic conditions. The company acquired global rights to two key molecules, targeting international expansion and expects continued volume-led growth in FY26.
-
Q2 FY25 saw 6% revenue growth and 13% EBITDA growth, driven by strong specialty product sales and new launches. Guidance was revised to 16% revenue growth and 100 bps EBITDA margin improvement for FY25, with inventory expected to normalize by year-end.
-
Q1 FY25 saw robust revenue and profit growth, driven by new product launches and strong herbicide demand, despite weather and logistics challenges. Leadership transition was completed, and FY25 guidance was upgraded to 18%-20% revenue growth, with margins expected to normalize.
Fiscal Year 2024
-
Acquisition of international rights for two fungicide products enables expansion into 20+ countries, with manufacturing to shift to India and expected 10%-15% CAGR over five years. The INR 165 crore deal leverages established brands and markets, aiming for stable margins and gradual revenue ramp-up.